Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search



Select publication to see the relevant sections.

Publication Date

    E.g., 2018-10-21
    E.g., 2018-10-21

Archive Search


100 items
5:40 PM, Oct 18, 2018  |  BC Innovations | Emerging Company Profile

Altheia: Proliferating PD-L1

Rather than blocking PD-L1 to treat cancer, Altheia Science s.r.l. is increasing expression of PD-L1 via a cell therapy to promote immune tolerance in autoimmune diseases, starting with Type I diabetes and multiple sclerosis. Altheia...
5:04 PM, Oct 11, 2018  |  BC Innovations | Emerging Company Profile

Spinogenix’s Spine Craft

Spinogenix Inc. is developing small molecules for cognitive impairment in neurodegenerative diseases that rebuilds dendritic spines to reverse, not just halt, synaptic loss. CNS synapses that relay signals involved in memory and cognitive function are formed...
2:44 PM, Oct 04, 2018  |  BC Innovations | Emerging Company Profile

Banking on exosomes

Alxerion Biotech LLC is building a biobank of exosomes from diverse species as a comprehensive source for therapeutics discovery. Its initial focus is on cancer. The company aims to collect and screen 350,000 samples from 30,000...
5:06 PM, Sep 27, 2018  |  BC Innovations | Emerging Company Profile

GDF11 against aging

Harvard University spinout Elevian Inc. is developing a regenerative platform around GDF11 to treat age-related diseases, including Alzheimer's disease. The company, which emerged from stealth on Sept. 6, aims to modulate the protein’s pathway with...
12:37 PM, Sep 20, 2018  |  BC Innovations | Emerging Company Profile

Recalcitrant Targets

With a fresh take on small molecule microarray technology, Kronos Bio Inc. aims to identify small molecule inhibitors of oncology targets considered undruggable, starting with a splice variant of the androgen receptor expressed in metastatic...
1:42 PM, Sep 13, 2018  |  BC Innovations | Emerging Company Profile

Mapping tumor markers

BioGraph 55 Inc. is mapping immune cells in the tumor microenvironment to identify cell-to-cell interaction patterns that can help match patients to existing therapies and identify novel therapeutic targets. The newco is developing a pipeline...
1:49 PM, Aug 29, 2018  |  BC Innovations | Emerging Company Profile

Meta(bolite) analysis

ClostraBio Inc.’s preclinical gut microbiome-derived metabolites could yield a pan-allergen therapy for food allergy, eschewing the need for multiple allergen-specific treatments. Director of Operations John Colson said research from co-founder and President Cathryn Nagler suggests microbial...
11:36 AM, Aug 23, 2018  |  BC Innovations | Emerging Company Profile

Bugs on film

Microbiome company Scioto Biosciences Inc. is turning a longstanding enemy of antibiotics developers -- biofilms -- into a delivery vehicle for probiotics. The company expects its lead candidate SB-121, an orally delivered biofilm formulation of Lactobacillus...
8:53 AM, Aug 15, 2018  |  BC Innovations | Emerging Company Profile

Breaking bad biofilms

Synspira LLC is developing glycopolymers against pulmonary disorders by targeting three mechanisms that exacerbate pulmonary decline: bacteria themselves, the mucus and biofilms that protect them and inflammation that leads to lasting tissue damage. Synspira in-licensed its...
11:40 AM, Aug 08, 2018  |  BC Innovations | Emerging Company Profile

Catching antibodies with polymers

Polyneuron Pharmaceuticals AG's glycopolymers act as decoys for the autoantibodies that drive autoimmune diseases, such as anti-MAG neuropathy, and are designed to be more effective and safer than other therapies. Polyneuron's Antibody-Catch platform generates glycopolymers that...